[1]SCHWENGER KJ, ALLARD JP.Clinical approaches to non-alcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (7) :1712-1723.
|
[2]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.
|
[3]MATO JM, LU SC.Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?[J].Hepatology, 2011, 54 (4) :1115-1117.
|
[4]MEHTA SR, THOMAS EL, BELL JD, et al.Non-invasive means of measuring hepatic fat content[J].Word J Gastroenterol, 2008, 14 (22) :3476-3483.
|
[5]CASTERA L, VILGRAIN V, ANGULO P.Noninvasive evaluation of NAFLD[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :666-675.
|
[6]SAADEH S, YOUNOSSI ZM, REMER EM, et al.The utility of radiological imaging in nonalcoholic fatty liver disease[J].Gastroenterology, 2002, 123 (3) :745-750.
|
[7]WONG VW, VERGNIOL J, WONG GL, et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (2) :454-462.
|
[8]VUPPALANCHI R, SIDDIQUI MS, van NATTA ML, et al.Performance characteristics of vibration-controlled transient elastography for evaluation of non-alcoholic fatty liver disease[J].Hepatology, 2017.[Epub ahead of print]
|
[9]CHEN J, TALWALKAR JA, YIN M, et al.Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography[J].Radiology, 2011, 259 (3) :749-756.
|
[10]TANG A, TAN J, SUN M, et al.Nonalcoholic fatty liver disease:MR imaging of liver proton density fat fraction to assess hepatic steatosis[J].Radiology, 2013, 267 (2) :422-431.
|
[11]CAO W, ZHAO C, SHEN C, et al.Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis[J].PLo S One, 2013, 8 (12) :e82092.
|
[12]YILMAZ Y, DOLAR E, ULUKAYA E, et al.Solubleforms of extracellular cytokeratin 18 may differentiatesimple steatosis from non-alcoholic steatohepatitis[J].World J Gastroenterol, 2007, 13 (6) :837-844.
|
[13]CHEN J, ZHU Y, ZHENG Q, et al.Serum cytokeratin-18 in the diagnosis of non-alcoholicsteatohepatitis:a meta-analysis[J].Hepatol Res, 2014, 44 (8) :854-862.
|
[14]GURTAN AM, SHARP PA.The role of miRNAs in regulating gene expression networks[J].J Mol Biol, 2013, 425 (19) :3582-3600.
|
[15]PIROLA CJ, FERNNDEZ GIANOTTI T, CASTAO GO, et al.Circulating microRNA signature in non-alcoholic fatty liver disease:from serum non-coding RNAs to liver histology and disease pathogenesis[J].Gut, 2015, 64 (5) :800-812.
|
[16]CERMELLI S, RUGGIERI A, MARRERO JA, et al.Circulating microRNAs in patients with chronic hepatitis C andnon-alcoholic fatty liver disease[J].PLo S One, 2011, 6 (8) :e23937.
|
[17]TARANTINO G, CONCA P, PASANISI F, et al.Could inflammatory markers help diagnosenonalcoholic steatohepatitis?[J].Eur JGastroenterol Hepatol, 2009, 21 (5) :504-511.
|
[18]YONEDA M, NOZAKI Y, ENDO H, et al.Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation[J].Dig Dis Sci, 2010, 55 (3) :808-814.
|
[19]KOWDLEY KV, BELT P, WILSON LA, et al.Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J].Hepatology, 2012, 55 (1) :77-85.
|
[20]YONEDA M, UCHIYAMA T, KATO S, et al.Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH) [J].BMCGastroenterol, 2008, 8 (1) :53.
|
[21]BOGA S, KOKSAL AR, ALKIM H, et al.Plasma Pentraxin 3 differentiates nonalcoholic steatohepatitis (NASH) from non-NASH[J].Metab Syndr Relat Disord, 2015, 13 (9) :393-399.
|
[22]POYNARD T, RATZIU V, CHARLOTTE F, et al.Diagnostic value of biochemical markers (Nash Test) for the prediction of nonalcoholic steatohepatitis in patients with non-alcoholic fatty liver disease[J].BMC Gastroenterol, 2006, 6:34.
|
[23]POYNARD T, LASSAILLY G, DIAZ E, et al.Performance of biomarkers Fibro Test, Acti Test, Steato Test, and Nash Test in patients with severe obesity:meta analysis of individual patient data[J].PLo S One, 2012, 7 (3) :e30325.
|
[24]HARRISON SA, OLIVER D, ARNOLD HL, et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease[J].Gut, 2008, 57 (10) :1441-1447.
|
[25]RASZEJA-WYSZOMIRSKA J, SZYMANIK B, AWNICZAK M, et al.Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD) [J].BMC Gastroenterol, 2010, 10:67.
|
[26]LEE TH, HAN SH, YANG JD, et al.Prediction of advanced fibrosis in nonalcoholic fatty liver disease:an enhanced model of BARDscore[J].Gut Liver, 2013, 7 (3) :323-328.
|